2015年版《临床用药须知》中含附子及其炮制品成方制剂收载情况及临床应用分析

Analysis of Set Prescription Preparations Containing Fuzi and Its Processed Products Recorded in 2015 Edition of Chinese Pharmacopeia Guidelines for Clinical Drug Use and Its Clinical Application

目的:为规范含附子及其炮制品成方制剂的临床应用提供参考。方法:查阅2015年版《中华人民共和国药典·临床用药须知》(以下简称《临床用药须知》),汇总、分析含附子及其炮制品成方制剂的收载情况,并检索CNKI数据库以整理其临床应用情况。结果:2015年版《临床用药须知》(中药成方制剂卷)中共收载含附子及其炮制品成方制剂55种,经过比对发现该书收载的相关品种存在炮制品名称不规范、标示不统一等现象。搜集到的临床应用报道共1131篇,涉及41个品种,其中以参附注射液、芪苈强心胶囊应用较多,但仍有14个品种未检索到相关临床应用报道。结论:应规范和统一附子炮制品名称,加强对附子相关制剂的研究,以有助于临床提高附子及其炮制品成方制剂的合理用药水平。

Objective:To provide reference for the rational use of set prescription preparations containing Fuzi(Aconiti Lateralis Radix Praeparata)and its processed products.Methods:The set prescription preparations containing Fuzi and its processed products were summarized and analyzed by consulting the 2015 edition of Chinese Pharmacopeia Guidelines for Clinical Drug Use.Their clinical applications were collected and sort out through the CNKI database.Results:A total of 55 set prescription preparations containing Fuzi and its processed products were recorded in the 2015 edition of Chinese Pharmacopeia Guidelines for Clinical Drug Use.It was found that the name and labeling of Fuzi and its processed products were not standard and uniform.A total of 1311 clinical application reports were collected from the database,involving 41 varieties.Shenfu injection and Qiliqiangxin capsules were widely used.There were still 14 varieties that had not been reported in relevant clinical application.Conclusion:It is necessary to standardize the name of the processed produts of Fuzi and strengthen the research on related preparations of Fuzi in order to improve the level of rational drug use of set prescription preparations containing Fuzi and its processed products in clinical practice.